Thyrocare Technologies

Diwali stock picks: ICICI Bk, ITC, Lodha can zoom up to 54% in Samvat 2081

5 stock ideas for Samvat 2081: ICICI Bank, ITC, Macrotech Developers, Varun Beverages and Thyrocare Technologies can rally up to 54%, suggests technical charts.

Thyrocare Tech stock skyrockets 17% post Q1FY25 results; details here

Thyrocare Technologies stock surged up to 16.75 per cent at Rs 759 per share on the BSE in Wednesday's intraday trade

Buzzing stocks, July 3:YES Bank, ZEE, DMart, IEX, Hindustan Zinc, KEC Int'l

Buzzing stocks to watch today, July 3: Avenue Supermarts, the DMart chain of stores' operator reported a provisional standalone revenue of Rs 13,712 crore for the June quarter, up 18 per cent Y-o-Y

Thyrocare completes acquisition of Think Health; stock hits 21-month high

Shares of Thyrocare Technologies hit a 21-month high of Rs 722 as they rallied 12 per cent on the BSE in Wednesday's intraday trade amid heavy volumes

Thyrocare surges 26% in two days amid fresh Covid-19 scare

Thyrocare is diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that centre on early detection and management of health disorders and diseases.

Healthcare stocks rally up to 8% as Covid cases spurt in China, Japan

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

Here's why Mehul Kothari recommends buying Metropolis, Thyrocare Tech

According to the technical analyst from Anand Rathi, Metropolis Healthcare can rally to Rs 1,800, while Thyrocare Technologies can rise up to Rs 740.

Fundsmith Emerging Equities sells Thyrocare shares worth Rs 36 crore

An entity on Monday offloaded 5.88 lakh shares of diagnostic chain Thyrocare Technologies Ltd for Rs 36 crore through an open market transaction. Fundsmith Emerging Equities Trust Plc sold 3,20,000 shares on BSE and 2,68,707 shares on NSE, amounting to a 1.1 per cent stake in the company, as per the bulk deal data available with the National Stock Exchange and BSE. The shares were disposed of at an average price of Rs 615.14 apiece on BSE and Rs 614.79 on NSE, taking the combined transaction value to Rs 36.20 crore. However, buyer(s) of the shares could not be ascertained. As of June quarter, Fundsmith held 1.15 per cent stake in the company, shareholding pattern showed with the exchange. Shares of Thyrocare Technologies closed 2.97 per cent lower at Rs 610 apiece on BSE and slipped 2.65 per cent on NSE.

Trading strategies for Thyrocare, Dr Lal Path, Metropolis amid Covid scare

Thyrocare, Dr Lal Path Labs and Metropolis are trading almost 50 per cent below their respective all-time highs, the reversal may see breakout if the key respective levels are sustained

Thyrocare Technologies names Rahul Guha as MD & CEO

A graduate of IIM-B, Guha has spent almost 17 years at Boston Consulting Group (BCG), where he has led the healthcare and life sciences practice

Thyrocare, Lal Pathlabs: Diagnostic stocks trade weak. Should you worry?

Given the weakness seen on Monday, should you be worried regarding stocks from this sector? Here is how they look on the charts

Thyrocare Technologies dips 7% as PharmaEasy offers to acquire 66% stake

Docon Technologies, along with API Holdings, the parent company of unicorn PharmEasy, also made an open offer for acquisition of additional 26% stake in Thyrocare at a price of Rs 1,300 per share

PharmEasy to pick up 66.1% stake in Thyrocare for Rs 4,546 crore

The combined entity will have the ability to provide diagnostics and pharmacy services to 100 million-plus Indians within 24 hours, the company said in a statement

Exploring windows to enhance shareholder value: Thyrocare Technologies

Thyrocare's market capitalisation is around Rs 6,916 crore. The deal thus could be for a shareholding in the firm

Nifty Pharma index hits new high; Aurobindo, Dr Reddy's gain over 3%

Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each

Testing recovery gains factored in Thyrocare Technologies stock

Margin pressures and valuations would limit major upsides

Surprise amid pandemic: Firms across sectors beat Q2 earnings expectations

Most brokerages have revised upwards their earnings estimates, not only for FY21, but also for FY22

Dr Lal PathLabs, Thyrocare slip on profit booking on Covid vaccine optimism

From March lows, the stock price of Thyrocare Technologies has been more-than-tripled and of Dr Lal PathLabs more-than-doubled on the BSE

Thyrocare rallies 10%, hits record high on expectation of strong Q2 results

Earlier this month, the company reported nearly 37 per cent year-on-year and over 100 per cent sequential growth in aggregate revenue for Q2FY21

Diagnostics players post healthy returns on quick rebound in business

Sharp rise in non-Covid business and strong revenue growth indicated by Thyrocare, Metropolis prop up sentiment